Lentiviral vectors for HIV disease prevention and treatment.
HIV/AIDS has posed major challenges to the scientific community, both in terms of treatment and prevention. Current drug regimens, while efficacious, are expensive, inaccessible to major parts of the world, induce major side effects, and cannot prevent escape mutants due to lack of compliance and drug fatigue. In the vaccine field, recent setbacks related to the interruption and cancellation of major advanced clinical trials using adenoviral vectors have highlighted the need for new and innovative strategies. Unique features of HIV-based lentiviral vectors (LVs) and the current progress in the LV-based platform development make them an attractive alternative for the further LV-based HIV vaccine development. In preclinical studies, they have demonstrated a high degree of immunogenicity, while overcoming pitfalls faced by other viral vectors. These findings, combined with recent progress in large scale LV production/purification, make this strategy worth considering for further vaccine development.
Lemiale
Franck
F
VIRxSYS Corporation, 200 Perry Parkway, Gaithersburg, MD 20877, United States. franck@virxsys.com
Korokhov
Nikolay
N
D016915:AIDS Vaccines / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D015658:HIV Infections / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D016086:Lentivirus / Q000235:genetics* / Q000254:growth & development / Q000276:immunology; D012449:Safety
D016915:AIDS Vaccines